Immunotherapy is a treatment procedure which enhances or supress the body’s immune system to fight against a disease. Immunotherapies which enhance the immune response are called as activation immunotherapies and those which reduce or suppress the immune response are called as suppression immunotherapies. Immunotherapy is of many types but the major immunotherapies for cancer include Monoclonal antibodies, Cancer vaccines and Non-specific immunotherapies.

According to a study uploaded to GitHub on February 27 that has not been peer reviewed, an emerging variant of SARS-CoV-2 first spotted in November in Manaus, Brazil and known as P.1 is around twice as transmissible as the variant that gripped the country last spring. Manaus experienced another surge of cases in December, and the study’s model predicts that P.1 could evade antibodies from previous infections 25–61 percent of the time, perhaps pointing to reinfections as a driver of the recent COVID-19 wave. A new modelling study by researchers in Brazil and the United Kingdom suggested that the Brazilian variant of Covid-19, known as P1, may be up to 2.2 times more transmissible and could evade immunity from previous Covid-19 infection by up to 61 per cent.

Kindly submit your manuscript at https://www.longdom.org/submissions/immunotherapy-open-access.html or you can mail through this mail id as an attachments immunother@emedsci.com 

Explore more information at Immunotherapy Open Access. You can share your experiences too by publishing your novel fact findings in this Journal.

Regards

Alex John
Immunotherapy Open Access
Editorial Manager     
E-mail id: immunotherapy@scholarlymed.com